Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer
BACKGROUND: High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the P...
Gespeichert in:
| Veröffentlicht in: | Cancer 2010-12, Vol.116 (24), p.5628-5636 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5636 |
|---|---|
| container_issue | 24 |
| container_start_page | 5628 |
| container_title | Cancer |
| container_volume | 116 |
| creator | de Haas, Esther C. Zwart, Nynke Meijer, Coby Suurmeijer, Albert J.H. Meijer, Karina Guchelaar, Henk‐Jan Hoekstra, Harald J. van Leeuwen, Flora E. Sleijfer, Dirk Th Boezen, H. Marike Gietema, Jourik A. |
| description | BACKGROUND:
High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the PAI‐1 promoter (rs1799889), which may influence PAI‐1 expression, is associated with survival and chemotherapy‐related vascular toxicity in testicular cancer (TC).
METHODS:
Data were collected on PAI‐1 4G/5G polymorphism, survival, venous thromboembolism (VTE), and coronary heart disease (CHD) for 324 non‐seminomatous TC patients treated with platinum‐based chemotherapy. Genotypes were compared regarding survival and disease outcome. VTE and CHD incidence were compared with adjustment for cardiovascular risk factors and prothrombotic gene polymorphisms of coagulation factors II/prothrombin (G20210A) and V (G1691A).
RESULTS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism shows a higher prevalence of International Germ Cell Cancer Classification (IGCCC) poor prognosis compared with 4G/5G and 5G/5G (24% vs 8% and 15%; chi‐square P = .003). In addition, the 4G/4G variant shows reduced TC‐related survival with a hazard ratio of 2.69 (95% CI, 1.26‐5.73; P = .010) for TC‐related death (adjusted for IGCCC). This is related to an increased risk for refractory disease and early relapses (odds ratio, 3.35; 95% CI, 1.48‐7.59; P = .004). PAI‐1 4G/5G polymorphism is not associated with VTE and CHD risk.
CONCLUSIONS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism may be an unfavorable prognostic as well as predictive factor for response to chemotherapy in TC patients. If confirmed, it may contribute to the identification of patients with increased risk for refractory disease. Cancer 2010. © 2010 American Cancer Society.
In this study the common 4G/4G variant of PAI‐1 4G/5G gene polymorphism is associated with reduced cancer‐related survival in testicular cancer patients treated with platinum‐based chemotherapy. This observation suggests that PAI‐1 (4G/5G polymorphism) may be an additional biomarker in testicular cancer and contribute to the identification of patients who are at increased risk of not responding to standard chemotherapy. |
| doi_str_mv | 10.1002/cncr.25300 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1238107691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1238105195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4570-190b2738b570cc5629c615ebfa87ae58150ac246ae97d0c399513a89004a05043</originalsourceid><addsrcrecordid>eNqN0c2KFDEQB_AgijuuXnwAyUUQoddK0ul0jsPgx8KiIgremppM2omkO23SPbt98xF8Rp_EjD3qTT2FCr9UhfoT8pDBBQPgz0xv4gWXAuAWWTHQqgBW8ttkBQB1IUvx8YzcS-lzLlVmd8kZByWUrOSK3KxTCsbh6EJPQ0vfri-_f_3G6CfbWzoEP3chDnuXOnrtxj1NUzy4A3qK_Y6ave3CuLcRhzk_itbjaHf0gMlMHiMdw40zbpyp6-lo0-iWa4O9sfE-udOiT_bB6TwnH148f795VVy9eXm5WV8VppQKCqZhy5Wot7kwRlZcm4pJu22xVmhlzSSg4WWFVqsdGKG1ZAJrDVAiSCjFOXmy9B1i-DLlXzSdS8Z6j70NU2oYFzUDVWn2n1QyLf9NgSldccUh06cLNTGkFG3bDNF1GOeMmmN-zTG_5md-GT869Z22nd39pr8Cy-DxCeQto29jXqZLf5yoJC_LYyO2uGvn7fyXkc3m9ebdMvwHIEaz_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1017962720</pqid></control><display><type>article</type><title>Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer</title><source>Wiley-Blackwell Free Backfiles(OpenAccess)</source><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>de Haas, Esther C. ; Zwart, Nynke ; Meijer, Coby ; Suurmeijer, Albert J.H. ; Meijer, Karina ; Guchelaar, Henk‐Jan ; Hoekstra, Harald J. ; van Leeuwen, Flora E. ; Sleijfer, Dirk Th ; Boezen, H. Marike ; Gietema, Jourik A.</creator><creatorcontrib>de Haas, Esther C. ; Zwart, Nynke ; Meijer, Coby ; Suurmeijer, Albert J.H. ; Meijer, Karina ; Guchelaar, Henk‐Jan ; Hoekstra, Harald J. ; van Leeuwen, Flora E. ; Sleijfer, Dirk Th ; Boezen, H. Marike ; Gietema, Jourik A.</creatorcontrib><description>BACKGROUND:
High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the PAI‐1 promoter (rs1799889), which may influence PAI‐1 expression, is associated with survival and chemotherapy‐related vascular toxicity in testicular cancer (TC).
METHODS:
Data were collected on PAI‐1 4G/5G polymorphism, survival, venous thromboembolism (VTE), and coronary heart disease (CHD) for 324 non‐seminomatous TC patients treated with platinum‐based chemotherapy. Genotypes were compared regarding survival and disease outcome. VTE and CHD incidence were compared with adjustment for cardiovascular risk factors and prothrombotic gene polymorphisms of coagulation factors II/prothrombin (G20210A) and V (G1691A).
RESULTS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism shows a higher prevalence of International Germ Cell Cancer Classification (IGCCC) poor prognosis compared with 4G/5G and 5G/5G (24% vs 8% and 15%; chi‐square P = .003). In addition, the 4G/4G variant shows reduced TC‐related survival with a hazard ratio of 2.69 (95% CI, 1.26‐5.73; P = .010) for TC‐related death (adjusted for IGCCC). This is related to an increased risk for refractory disease and early relapses (odds ratio, 3.35; 95% CI, 1.48‐7.59; P = .004). PAI‐1 4G/5G polymorphism is not associated with VTE and CHD risk.
CONCLUSIONS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism may be an unfavorable prognostic as well as predictive factor for response to chemotherapy in TC patients. If confirmed, it may contribute to the identification of patients with increased risk for refractory disease. Cancer 2010. © 2010 American Cancer Society.
In this study the common 4G/4G variant of PAI‐1 4G/5G gene polymorphism is associated with reduced cancer‐related survival in testicular cancer patients treated with platinum‐based chemotherapy. This observation suggests that PAI‐1 (4G/5G polymorphism) may be an additional biomarker in testicular cancer and contribute to the identification of patients who are at increased risk of not responding to standard chemotherapy.</description><identifier>ISSN: 0008-543X</identifier><identifier>ISSN: 1097-0142</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.25300</identifier><identifier>PMID: 20737565</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Cardiovascular Diseases - chemically induced ; Factor V - genetics ; gene polymorphism ; Gynecology. Andrology. Obstetrics ; Humans ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; PAI‐1 ; Plasminogen Activator Inhibitor 1 - genetics ; Platinum Compounds - adverse effects ; Platinum Compounds - therapeutic use ; Polymorphism, Genetic ; Prognosis ; Prothrombin - genetics ; Risk Factors ; survival ; testicular cancer ; Testicular Neoplasms - drug therapy ; Testicular Neoplasms - genetics ; Testicular Neoplasms - mortality ; Tumors ; vascular toxicity</subject><ispartof>Cancer, 2010-12, Vol.116 (24), p.5628-5636</ispartof><rights>Copyright © 2010 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4570-190b2738b570cc5629c615ebfa87ae58150ac246ae97d0c399513a89004a05043</citedby><cites>FETCH-LOGICAL-c4570-190b2738b570cc5629c615ebfa87ae58150ac246ae97d0c399513a89004a05043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.25300$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.25300$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23652440$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20737565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Haas, Esther C.</creatorcontrib><creatorcontrib>Zwart, Nynke</creatorcontrib><creatorcontrib>Meijer, Coby</creatorcontrib><creatorcontrib>Suurmeijer, Albert J.H.</creatorcontrib><creatorcontrib>Meijer, Karina</creatorcontrib><creatorcontrib>Guchelaar, Henk‐Jan</creatorcontrib><creatorcontrib>Hoekstra, Harald J.</creatorcontrib><creatorcontrib>van Leeuwen, Flora E.</creatorcontrib><creatorcontrib>Sleijfer, Dirk Th</creatorcontrib><creatorcontrib>Boezen, H. Marike</creatorcontrib><creatorcontrib>Gietema, Jourik A.</creatorcontrib><title>Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the PAI‐1 promoter (rs1799889), which may influence PAI‐1 expression, is associated with survival and chemotherapy‐related vascular toxicity in testicular cancer (TC).
METHODS:
Data were collected on PAI‐1 4G/5G polymorphism, survival, venous thromboembolism (VTE), and coronary heart disease (CHD) for 324 non‐seminomatous TC patients treated with platinum‐based chemotherapy. Genotypes were compared regarding survival and disease outcome. VTE and CHD incidence were compared with adjustment for cardiovascular risk factors and prothrombotic gene polymorphisms of coagulation factors II/prothrombin (G20210A) and V (G1691A).
RESULTS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism shows a higher prevalence of International Germ Cell Cancer Classification (IGCCC) poor prognosis compared with 4G/5G and 5G/5G (24% vs 8% and 15%; chi‐square P = .003). In addition, the 4G/4G variant shows reduced TC‐related survival with a hazard ratio of 2.69 (95% CI, 1.26‐5.73; P = .010) for TC‐related death (adjusted for IGCCC). This is related to an increased risk for refractory disease and early relapses (odds ratio, 3.35; 95% CI, 1.48‐7.59; P = .004). PAI‐1 4G/5G polymorphism is not associated with VTE and CHD risk.
CONCLUSIONS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism may be an unfavorable prognostic as well as predictive factor for response to chemotherapy in TC patients. If confirmed, it may contribute to the identification of patients with increased risk for refractory disease. Cancer 2010. © 2010 American Cancer Society.
In this study the common 4G/4G variant of PAI‐1 4G/5G gene polymorphism is associated with reduced cancer‐related survival in testicular cancer patients treated with platinum‐based chemotherapy. This observation suggests that PAI‐1 (4G/5G polymorphism) may be an additional biomarker in testicular cancer and contribute to the identification of patients who are at increased risk of not responding to standard chemotherapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Factor V - genetics</subject><subject>gene polymorphism</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>PAI‐1</subject><subject>Plasminogen Activator Inhibitor 1 - genetics</subject><subject>Platinum Compounds - adverse effects</subject><subject>Platinum Compounds - therapeutic use</subject><subject>Polymorphism, Genetic</subject><subject>Prognosis</subject><subject>Prothrombin - genetics</subject><subject>Risk Factors</subject><subject>survival</subject><subject>testicular cancer</subject><subject>Testicular Neoplasms - drug therapy</subject><subject>Testicular Neoplasms - genetics</subject><subject>Testicular Neoplasms - mortality</subject><subject>Tumors</subject><subject>vascular toxicity</subject><issn>0008-543X</issn><issn>1097-0142</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c2KFDEQB_AgijuuXnwAyUUQoddK0ul0jsPgx8KiIgremppM2omkO23SPbt98xF8Rp_EjD3qTT2FCr9UhfoT8pDBBQPgz0xv4gWXAuAWWTHQqgBW8ttkBQB1IUvx8YzcS-lzLlVmd8kZByWUrOSK3KxTCsbh6EJPQ0vfri-_f_3G6CfbWzoEP3chDnuXOnrtxj1NUzy4A3qK_Y6ave3CuLcRhzk_itbjaHf0gMlMHiMdw40zbpyp6-lo0-iWa4O9sfE-udOiT_bB6TwnH148f795VVy9eXm5WV8VppQKCqZhy5Wot7kwRlZcm4pJu22xVmhlzSSg4WWFVqsdGKG1ZAJrDVAiSCjFOXmy9B1i-DLlXzSdS8Z6j70NU2oYFzUDVWn2n1QyLf9NgSldccUh06cLNTGkFG3bDNF1GOeMmmN-zTG_5md-GT869Z22nd39pr8Cy-DxCeQto29jXqZLf5yoJC_LYyO2uGvn7fyXkc3m9ebdMvwHIEaz_g</recordid><startdate>20101215</startdate><enddate>20101215</enddate><creator>de Haas, Esther C.</creator><creator>Zwart, Nynke</creator><creator>Meijer, Coby</creator><creator>Suurmeijer, Albert J.H.</creator><creator>Meijer, Karina</creator><creator>Guchelaar, Henk‐Jan</creator><creator>Hoekstra, Harald J.</creator><creator>van Leeuwen, Flora E.</creator><creator>Sleijfer, Dirk Th</creator><creator>Boezen, H. Marike</creator><creator>Gietema, Jourik A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U1</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20101215</creationdate><title>Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer</title><author>de Haas, Esther C. ; Zwart, Nynke ; Meijer, Coby ; Suurmeijer, Albert J.H. ; Meijer, Karina ; Guchelaar, Henk‐Jan ; Hoekstra, Harald J. ; van Leeuwen, Flora E. ; Sleijfer, Dirk Th ; Boezen, H. Marike ; Gietema, Jourik A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4570-190b2738b570cc5629c615ebfa87ae58150ac246ae97d0c399513a89004a05043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Factor V - genetics</topic><topic>gene polymorphism</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>PAI‐1</topic><topic>Plasminogen Activator Inhibitor 1 - genetics</topic><topic>Platinum Compounds - adverse effects</topic><topic>Platinum Compounds - therapeutic use</topic><topic>Polymorphism, Genetic</topic><topic>Prognosis</topic><topic>Prothrombin - genetics</topic><topic>Risk Factors</topic><topic>survival</topic><topic>testicular cancer</topic><topic>Testicular Neoplasms - drug therapy</topic><topic>Testicular Neoplasms - genetics</topic><topic>Testicular Neoplasms - mortality</topic><topic>Tumors</topic><topic>vascular toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Haas, Esther C.</creatorcontrib><creatorcontrib>Zwart, Nynke</creatorcontrib><creatorcontrib>Meijer, Coby</creatorcontrib><creatorcontrib>Suurmeijer, Albert J.H.</creatorcontrib><creatorcontrib>Meijer, Karina</creatorcontrib><creatorcontrib>Guchelaar, Henk‐Jan</creatorcontrib><creatorcontrib>Hoekstra, Harald J.</creatorcontrib><creatorcontrib>van Leeuwen, Flora E.</creatorcontrib><creatorcontrib>Sleijfer, Dirk Th</creatorcontrib><creatorcontrib>Boezen, H. Marike</creatorcontrib><creatorcontrib>Gietema, Jourik A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Haas, Esther C.</au><au>Zwart, Nynke</au><au>Meijer, Coby</au><au>Suurmeijer, Albert J.H.</au><au>Meijer, Karina</au><au>Guchelaar, Henk‐Jan</au><au>Hoekstra, Harald J.</au><au>van Leeuwen, Flora E.</au><au>Sleijfer, Dirk Th</au><au>Boezen, H. Marike</au><au>Gietema, Jourik A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2010-12-15</date><risdate>2010</risdate><volume>116</volume><issue>24</issue><spage>5628</spage><epage>5636</epage><pages>5628-5636</pages><issn>0008-543X</issn><issn>1097-0142</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the PAI‐1 promoter (rs1799889), which may influence PAI‐1 expression, is associated with survival and chemotherapy‐related vascular toxicity in testicular cancer (TC).
METHODS:
Data were collected on PAI‐1 4G/5G polymorphism, survival, venous thromboembolism (VTE), and coronary heart disease (CHD) for 324 non‐seminomatous TC patients treated with platinum‐based chemotherapy. Genotypes were compared regarding survival and disease outcome. VTE and CHD incidence were compared with adjustment for cardiovascular risk factors and prothrombotic gene polymorphisms of coagulation factors II/prothrombin (G20210A) and V (G1691A).
RESULTS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism shows a higher prevalence of International Germ Cell Cancer Classification (IGCCC) poor prognosis compared with 4G/5G and 5G/5G (24% vs 8% and 15%; chi‐square P = .003). In addition, the 4G/4G variant shows reduced TC‐related survival with a hazard ratio of 2.69 (95% CI, 1.26‐5.73; P = .010) for TC‐related death (adjusted for IGCCC). This is related to an increased risk for refractory disease and early relapses (odds ratio, 3.35; 95% CI, 1.48‐7.59; P = .004). PAI‐1 4G/5G polymorphism is not associated with VTE and CHD risk.
CONCLUSIONS:
The 4G/4G variant of PAI‐1 4G/5G polymorphism may be an unfavorable prognostic as well as predictive factor for response to chemotherapy in TC patients. If confirmed, it may contribute to the identification of patients with increased risk for refractory disease. Cancer 2010. © 2010 American Cancer Society.
In this study the common 4G/4G variant of PAI‐1 4G/5G gene polymorphism is associated with reduced cancer‐related survival in testicular cancer patients treated with platinum‐based chemotherapy. This observation suggests that PAI‐1 (4G/5G polymorphism) may be an additional biomarker in testicular cancer and contribute to the identification of patients who are at increased risk of not responding to standard chemotherapy.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20737565</pmid><doi>10.1002/cncr.25300</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2010-12, Vol.116 (24), p.5628-5636 |
| issn | 0008-543X 1097-0142 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1238107691 |
| source | Wiley-Blackwell Free Backfiles(OpenAccess); MEDLINE; Wiley Blackwell Single Titles; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Adolescent Adult Aged Biological and medical sciences Cardiovascular Diseases - chemically induced Factor V - genetics gene polymorphism Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged PAI‐1 Plasminogen Activator Inhibitor 1 - genetics Platinum Compounds - adverse effects Platinum Compounds - therapeutic use Polymorphism, Genetic Prognosis Prothrombin - genetics Risk Factors survival testicular cancer Testicular Neoplasms - drug therapy Testicular Neoplasms - genetics Testicular Neoplasms - mortality Tumors vascular toxicity |
| title | Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A54%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20PAI%E2%80%901%20gene%20polymorphism%20with%20survival%20and%20chemotherapy%E2%80%90related%20vascular%20toxicity%20in%20testicular%20cancer&rft.jtitle=Cancer&rft.au=de%20Haas,%20Esther%20C.&rft.date=2010-12-15&rft.volume=116&rft.issue=24&rft.spage=5628&rft.epage=5636&rft.pages=5628-5636&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.25300&rft_dat=%3Cproquest_cross%3E1238105195%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1017962720&rft_id=info:pmid/20737565&rfr_iscdi=true |